Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMASCIS-02 allogeneic adipose-derived MSCs in ischemic stroke
2024-512514-18-00Phase 2Authorised
- Sponsor
- FIBHULP
- Start
- Apr 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Allogeneic adipose-derived mesenchymal stem cells with Placebo (2 arms). Primary endpoint: Safety of mesenchymal stem cells from adipose tissue. Planned start Apr 2024; status: authorised.
02
Drugs
CSCC_ASC
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-512514-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512514-18-00.